Vanguard Group Inc. grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,060,730 shares of the medical research company’s stock after acquiring an additional 27,217 shares during the period. Vanguard Group Inc. owned about 10.62% of Charles River Laboratories International worth $511,893,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in CRL. Northern Trust Corp increased its stake in shares of Charles River Laboratories International by 1.5% during the 2nd quarter. Northern Trust Corp now owns 436,860 shares of the medical research company’s stock worth $44,188,000 after purchasing an additional 6,304 shares during the last quarter. Van ECK Associates Corp raised its holdings in shares of Charles River Laboratories International by 13.0% in the 2nd quarter. Van ECK Associates Corp now owns 148,282 shares of the medical research company’s stock valued at $14,999,000 after purchasing an additional 17,097 shares during the period. UBS Asset Management Americas Inc. raised its holdings in shares of Charles River Laboratories International by 22.6% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 109,141 shares of the medical research company’s stock valued at $11,040,000 after purchasing an additional 20,133 shares during the period. Quantitative Investment Management LLC bought a new stake in shares of Charles River Laboratories International in the 2nd quarter valued at about $394,000. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Charles River Laboratories International by 1.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 22,974 shares of the medical research company’s stock valued at $2,324,000 after purchasing an additional 242 shares during the period. 95.37% of the stock is owned by institutional investors.

Several brokerages recently issued reports on CRL. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 target price for the company in a research note on Wednesday, July 12th. Jefferies Group LLC reissued a “buy” rating and set a $121.00 price target on shares of Charles River Laboratories International in a research report on Friday, June 30th. BidaskClub lowered Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Robert W. Baird restated a “buy” rating and issued a $114.00 price objective on shares of Charles River Laboratories International in a research note on Friday, September 1st. Finally, Barclays PLC reiterated a “hold” rating and set a $102.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Six equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Charles River Laboratories International presently has an average rating of “Buy” and an average target price of $99.59.

In other Charles River Laboratories International news, Chairman James C. Foster sold 9,516 shares of the business’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $98.92, for a total value of $941,322.72. Following the transaction, the chairman now directly owns 361,171 shares in the company, valued at $35,727,035.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Davide Molho sold 5,982 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $107.55, for a total transaction of $643,364.10. Following the transaction, the insider now directly owns 22,714 shares of the company’s stock, valued at $2,442,890.70. The disclosure for this sale can be found here. Insiders have sold 25,880 shares of company stock valued at $2,541,668 in the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

Charles River Laboratories International, Inc. (CRL) opened at 108.93 on Tuesday. The firm has a market cap of $5.18 billion, a P/E ratio of 28.70 and a beta of 0.96. The stock has a 50 day moving average price of $105.51 and a 200 day moving average price of $96.80. Charles River Laboratories International, Inc. has a 52-week low of $67.20 and a 52-week high of $109.59.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.07. The company had revenue of $469.13 million for the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The firm’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.20 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Charles River Laboratories International, Inc. (CRL) Holdings Increased by Vanguard Group Inc.” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/charles-river-laboratories-international-inc-crl-holdings-increased-by-vanguard-group-inc/1605062.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.